MetaCap

Inhibikase Therapeutics Inc. (IKT)

NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.32+0.02 (+1.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IKT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$185.16M
EPS (TTM)
-$0.40
52-week range
1.28 – 2.61
Day range
1.28 – 1.37
Volume / Avg
1.11M / 584.27K
Beta
—

52-week range

$1.28$2.61

IKT stock today

Inhibikase Therapeutics (IKT) closed at $1.32 on Nov 20, up 1.54% (+$0.02), versus the S&P 500's 3.70% decline. At this level, IKT sits near the bottom of its 52-week range of $1.28 to $2.61: 49.4% below the high, set on Sep 3, 2026 and 3.1% above the low. IKT is down 35.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.4%.

Inhibikase Therapeutics has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Inhibikase Therapeutics

Company profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Mark T. Iwicki
Headquarters
Wilmington, DE
Employees
35
IPO year
2020

Financial highlights

Full financials

Inhibikase Therapeutics reported a net loss of $48.3 million, compared with a loss of $27.5 million a year earlier. Diluted earnings per share came in at -$0.49.

Inhibikase Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$0$260.50K$123.44K$3.10M
Growth—-100.00%+111.03%-96.02%+343.92%
Net income$-48.26M$-27.52M$-19.03M$-18.05M$-14.79M
EPS (diluted)$-0.49$-1.16$-3.16$-4.28$-0.81

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$5.55+320.45%

  • Strong buy 1
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $1.50High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.10 vs $-0.11
Surprise
+9.09%

IKT news

All IKT news

Inhibikase Therapeutics peers

Health Care sector
IKT peer companies
CompanyPrice% ChgMarket capCompare
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs IKT
CGENCompugen Ltd.1.84-2.13%$174.29Mvs IKT
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs IKT
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs IKT
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs IKT
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs IKT
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs IKT
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs IKT

Indexes, lists and sector

Inhibikase Therapeutics stock FAQ

What is Inhibikase Therapeutics's stock price today?

IKT last traded at $1.32 as of Nov 20, 4:00 PM EST, up 1.54% on the day. Prices are delayed at least 15 minutes.

Does Inhibikase Therapeutics pay a dividend?

No. Inhibikase Therapeutics does not currently pay a regular cash dividend.

Who is Inhibikase Therapeutics's CEO?

Mr. Mark T. Iwicki is the chief executive officer of Inhibikase Therapeutics Inc., which has about 35 employees.

Has IKT ever split its stock?

Yes. The most recent IKT stock split was a 1-for-6 split on Jun 30, 2023.

What is the IKT 52-week high?

The 52-week high for IKT is $2.61 and the 52-week low is $1.28. The stock is currently 49.4% below its high.

Compare IKT